Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins

Oncotarget

Volumn 5, Issue 12, 2014, Pages 3983-3995

  O'Shannessy, Daniel J ^a   Somers, Elizabeth B ^a   Chandrasekaran, Lakshmi K ^b   Nicolaides, Nicholas C ^a   Bordeaux, Jennifer ^b   Gustavson, Mark D ^b  

^a Morphotek Inc   (United States)

^b Genoptix Inc   (United States)

Author keywords

CRC; Endosialin; Prognosis; TEM 1; Tumor microenvironment

Indexed keywords

COLLAGEN TYPE 4; ENDOSIALIN; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9G5; TUMOR MARKER; UNCLASSIFIED DRUG; CD248 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROCESS DEVELOPMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; TISSUE STRUCTURE; TUMOR ENDOTHELIAL MARKER 1 ASSOCIATED PATHWAY PROGNOSTIC SIGNATURE; TUMOR MICROENVIRONMENT; COLORECTAL TUMOR; GENE EXPRESSION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ANTIGENS, CD; ANTIGENS, NEOPLASM; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84905081437     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2108     Document Type: Article

References (40)

1. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59: 5002-5011.
2. Schurch W, Seemayer TA, Lagace, R. Stromal myofibroblasts in primary invasive and metastatic carcinomas. A combined immunological, light and electron microscopic study. Ows Virch Arch. 1981; 391: 125-139.
3. Elenbaas B, Weinberg RA. Heterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma Formation. Exp Cell Res. 2001; 264: 169-184.
4. Montesano R, Schaller G, Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell. 1991; 66: 697-711.
5. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986; 315: 1650-1659.
6. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA. 1993; 90: 393-397.
7. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407: 242-248.
8. Simonavicius N, Ashenden M, van Weverwijk A, Lax S, Huso DL, Buckley CD et al. Pericytes promote selective vessel regression to regulate vascular patterning. Blood. 2012; 120: 1516-1527.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-257.
10. Rmali KA, Puntis MC, Jiang WG. Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol. 2005; 11: 1283-1286.
11. Bagley RG. Endosialin: from vascular target to biomarker for human sarcomas. Biomark Med. 2009; 3: 589-604.
12. Bagley RG, Honma N, Weber W, Boutin P, Rouleau C, Shankara S et al. TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res. 2008; 76: 180-188.
13. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A. 1992; 89: 10832-10836.
14. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. Genes expressed in human tumor endothelium. Science. 2000; 289: 1197-1202.
15. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 1999; 5: 1041-1056.
16. Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin. Exp. Metastasis. 2004; 21: 31-37.
17. Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 2005; 5: 10.
18. Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E et al. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol. 2011; 39: 73-89.
19. Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello Jet al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res. 2008; 14: 7223-7236.
20. Huber MA, Kraut N, Schweifer N, Dolznig H, Peter RU, Schubert RD et al. Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol. 2006; 33: 145-55.
21. Brady J, Neal J, Sadakar N, Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004; 63: 1274-1283.
22. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003; 314: 15-23.
23. Díaz-Flores L, Gutiérrez R, Madrid JF, Varela H, Valladares F, Acosta E et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol. 2009; 24: 909-969.
24. Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A. 2006; 103: 3351-335.
25. Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E et al. Expression of Human Endosialin (CD248) Promotes Cellular Adhesion to Fibronectin Through Direct Binding and Activation of β1 Integrins. Proc Natl Acad Sci. 2007; 104: 17965-17970.
26. Hardie DL, Baldwin MJ, Naylor A, Haworth OJ, Hou TZ, Lax S et al. The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation. Immunology. 2011; 133: 288-295.
27. Tomkowicz B, Rybinski K, Sebeck D, Sass PM, Nicolaides NC, Grasso L, Zhou Y. TEM-1/CD248 Regulates Pericyte Proliferation through PDGF Receptor Signaling. Cancer Biol. Ther. 2010; 9: 1-8.
28. Carvajal RD, Gounder MM, Coughlin CM, Fishel J, Heyburn J, O'Shannessy D, Grasso L, Schweizer C, Parno J, Old LJ, Azad NS, Diaz LA. A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. J Clin Oncol 2001; 29.
29. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005; 25: 5675-86.
30. C.C. Wykoff, N.J.P. Beasley, P.H. Watson, K.J. Turner, J. Pastorek, A. Sibtain, G.D. Wilson, H. Turley, K.L. Talks, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, A.L. Harris. Hypoxia-inducible Expression of Tumor-associated Carbonic Anhydrases. Cancer Res. 60, 7075-7083 (2000).
31. Ohradanova Al, Gradin K, Barathova M, Zatovicova M, Holotnakova T, Kopacek J, et al. Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer. 2008; 99: 1348-56.
32. Maia M, DeVriese A, Janssens T, Moons M, Lories RJ, Tavernier J, Conway EM. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011; 11: 162.
33. Lax S, Hardie DL, Wilson A, Douglas MR, Anderson G, Huso D, Isacke CM, Buckley CD. The pericyte and stromal cell marker CD248 (endosialin) is required for efficient lymph node expansion. Eur J Immunol. 2010; 40: 1884-1889.
34. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008; 26: 5630-5637.
35. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol. 2004; 1: 104-111.
36. Gustavson MD, Bourke-Martin B, Reilly DM, Cregger M, Williams C, Mayotte J, Zerkowski M, Tedeschi G, Pinard R, Christiansen J. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med. 2009; 133: 1413-1419.
37. Gustavson MD, Bourke-Martin B, Reilly DM, Cregger M, Williams C, Tedeschi G, Pinard R, Christiansen J. Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis. Appl Immunohistochem Mol Morphol. 2009; 17: 329-337.
38. O'Shannessy DJ, Gustavson M, Chandrasekaran LK, Dolled-Filhart M, Somers EB. Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology. Biomark Med. 2013; 7: 933-946.
39. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003; 34: 374-378.
40. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10: 7252-7259.